Company Analysis
Sign in

Atossa Therapeutics, Inc. (ATOS)

Nasdaq: ATOS · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 2010
Full chart Alerts Compare
Grade4.9
◀ Past 4.4● Present 5.6▶ Future 4.5
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Atossa Therapeutics, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.9/10
◀ Past4.425% of the headline
● Present5.635% of the headline
▶ Future4.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.1/10

Has it survived what it has been through?

13 warning events since 2017; the latest 2026-02-17.

weight 22% of this tense · 11th percentile among 497 sector filers · read for itself

From the record

Atossa Therapeutics, Inc.'s filings since 2017 show 13 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 11 times, the latest 2026-02-17); a warning not to rely on past financial statements (8-K item 4.02, the latest 2018-11-13); an auditor change (8-K item 4.01, the latest 2023-05-22) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.1/10

What has it actually done, year after year?

+4% a year over 5 filed years; profit years unseen.

weight 45% of this tense · 31st percentile among 323 sector filers · read for its customers

From the record

Atossa Therapeutics, Inc.'s 5 filed years say what it did: revenue went from $2 thousand in fiscal 2011 to $2 thousand in fiscal 2015, up 4% a year; it rose in 2 of 4 years; the deepest fall was 100% from fiscal 2013 to fiscal 2015 (its annual reports).

What it rests on

  • revenue growth over the filed span4.0%bottom 34% of its family
  • the share of years revenue rosebottom 36% of its family
  • the deepest fall from a revenue peak99.7%bottom 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
8.5/10

How has it treated the people who own it?

SI estimate 8.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 85th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Atossa Therapeutics, Inc.'s shareholder treatment is put at 8.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 15% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.6/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
6.1/10

Is it financially healthy right now?

ROE -88%: lost 88¢ per shareholder dollar. Leverage 17%: owes 17¢ per asset dollar.

weight 45% of this tense · 61st percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Atossa Therapeutics, Inc. lost about 88 cents for every dollar of shareholders' money. Leverage: it owed about 17 cents per dollar of assets, and net share issuance: its share count grew 2.6% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 28% of its family
  • return on equitybottom 34% of its family
  • the share count against the year beforetop 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.1/10

How strong is its position in its industry?

bottom 1% of 315 in its family.

weight 22% of this tense · 1st percentile among 315 sector filers · read for its customers

From the record

Atossa Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $2 thousand in fiscal 2015 ranks in the bottom 1% by size; revenue growth of -84.6% a year over the last 3 filed years ranks in the bottom 2% (its annual reports).

What it rests on

  • revenue against the family$1758.00bottom 1% of its family
  • three-year revenue growth-84.6%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
8.4/10

What are the people in charge doing?

top 16% of 315 in its family for leadership; chief executive since 2012.

weight 33% of this tense · 84th percentile among 315 sector filers · read for its shareholders

From the record

Atossa Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Quay, Steven C (President & CEO, as filed), filing under that title since 2012-11-07, 14 years (top 7% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 13.4 years (top 3%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge3 in three years among 8 peopletop 39% of its family
  • the median years the people in charge have filed13.4 yearstop 3% of its family
  • the chief executive's years on the record14.0 yearstop 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.5/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
8.7/10

How much room does it have to grow?

SI estimate 8.7/10, confidence 35 of 100 (one part).

weight 33% of this tense · 87th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 13% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Atossa Therapeutics, Inc.'s room to expand is put at 8.7 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 13% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
3.2/10

What could actually drive growth from here?

bottom 32% of 306 in its family for growth drivers.

weight 45% of this tense · 32nd percentile among 306 sector filers · read for its customers

From the record

Atossa Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2015: revenue grew -84.6% a year over the last three filed years against 4% over all 5, slowing (bottom 5% of its family); the newest year grew -95.6% (bottom 3%); research spending grew 12% a year (top 36%); capital spending grew -5.2% a year (top 43%) (its annual reports). Atossa Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-88.7 points a yearbottom 5% of its family
  • the newest year's revenue growth-95.6%bottom 3% of its family
  • three-year growth of research spending12.0%top 36% of its family
  • three-year growth of capital spending-5.2%top 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
0.8/10

Did its newest year beat what its own record pointed to?

SI estimate 0.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 8th percentile among 284 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, revenue against the prior three years' pace, which ranks in the bottom 8% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: revenue against the prior three years' pace, the one part on file, ranked among 284 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Atossa Therapeutics, Inc.'s expectations vs reality is put at 0.8 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the prior three years' pace, which ranks in the bottom 8% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ATOS · research, not advice